Bachem hosting webinar on Peptide Easy Clean (PEC) technology

Bubendorf, Switzerland: –Peptide technology specialist Bachem will host an online webinar later this month on Peptide Easy Clean (PEC) technology and its application for a traceless parallel purification of complex peptides.

The free webinar Peptide Easy Clean (PEC): A New Turn in Peptide Purification will last one hour, commencing 1000hrs CET (UTC +1) on February 25, 2021. Registration is free of charge and can be completed online (see Resources).

Purification challenge

Purification of peptides presents an industry-wide challenge, especially in processing diverse peptide libraries, due to their potentially broad distribution in physico-chemical properties.

The webinar will highlight the advantages of Berlin-based Belyntic’s universally applicable Peptide Easy Clean (PEC) technology and its potential for more efficient and innovative development of new peptide based drug modalities.

PEC technology

Unlike high-pressure liquid chromatography (HPLC) that only allows sequential processing of single samples, PEC can be used for parallel purifications, increasing the speed of peptide development. In addition, by using PEC methodology, aggregation or precipitation can be prevented and increased solubility in organic solvents achieved.

The Peptide Easy Clean technology will be presented by Belyntic GmbH co-founder and Head of R&D, Dr. Robert Zitterbart, who has almost a decade of experience in the development of peptide purification technologies. After his diploma work in the group of K. Peter C. Vollhardt at the University of California, Berkeley, Robert Zitterbart earned his Ph.D. at Humboldt-University, Berlin in the group of Oliver Seitz. During his scientific career, he has successfully published many articles in peer reviewed journals.

PEC advantages and applications

Bachem was a key partner in the development of PEC with early testing on pharmaceutically relevant peptides. Potential advantages and applications of PEC technology will be explained by Dr. Gavin Noble, R&D Chemist at Bachem (UK) Ltd. Dr. Noble will focus on the potential for traceless parallel peptide purification using a first-in-class reductively cleavable linker system featuring a safety-release.

Dr. Noble’s primary focus at Bachem UK in St Helens is undertaking and coordinating investigations into new production methods for research-grade peptide manufacture, as well as supporting the Synthesis and Purification groups as a ‘troubleshooter’.

Dr. Noble joined Bachem in 2014., following an eminent research career at University of Manchester, UK, performing research into protein and enzyme activity at synthetic liposome surfaces and as a post-doctoral fellow at The University of Notre Dame (USA), researching peptide-targeted liposome nanoparticles for cancer and antimalarial therapies. During his career, he has published several peer-reviewed articles in high-impact journals, with over 600 citations.

About Bachem

The Swiss based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of pepTides, oligonucleoTides and complex organic molecules as active pharmaceutical ingredients (APIs). A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.

With 50 years of experience, headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.

Under its banner Leading Partner in Tides, Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.

Bachem has five production sites in the US, UK and Switzerland along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, and new chemical entities (NCEs) at preclinical, clinical and production scales.

Further information at: www.bachem.com

Resources

Click on Bachem webinar ‘Peptide Easy Clean (PEC): A New Turn in Peptide Purification’ to register for the event.
Click on Bachems News to see latest News & Events.